SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid

Event · Clinical / regulatory
Product
galinpepimut-S (GPS)
Milestone
topline data
Indication
acute myeloid leukemia (AML)

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 17, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLS
Bullish
high confidence
Mentioned
$SLS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SLSBullishMed
01

Why it matters

The disclosure provides newly reported, statistically significant overall survival improvement versus investigator’s choice of best available treatment, plus a stated plan to meet the FDA and prepare for a BLA submission in 1H 2027 using an accelerated filing strategy.

02

Market read

Traders can reassess near-term biotech risk as the company moves from late-stage clinical uncertainty toward a defined regulatory pathway with accelerated BLA preparations.

03

What to watch

FDA feedback on accelerated filing strategy and the eventual BLA review timeline remain key uncertainties, and the trial’s open-label design could affect interpretation despite the OS endpoint.

Relevance 8/10Novelty 9/10Timing: webcast today, Nov. 17, 2026 at 7:45 a.m. ET

Background

The 8-K (Item 7.01 Regulation FD, Item 8.01 Other Events) announces topline results from the pivotal randomized Phase 3 REGAL trial of galinpepimut-S (GPS) as AML maintenance monotherapy in patients ineligible for or unable to undergo allogeneic stem cell transplantation.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

SELLAS reports positive pivotal Phase 3 REGAL OS results for galinpepimut-S, including HR 0.59 (p=0.035) and plans for FDA BLA discussions.

Expected impact

Likely upward bias as investors price in improved FDA odds and a clearer path to an accelerated BLA filing timeline.

Evidence & confidence

The filing plan (accelerated strategy, BLA prep in 1H 2027) is directly tied to the newly disclosed primary endpoint results, which are typically material for biotech valuation and near-term sentiment.

Market effects

Adds incremental validation for WT1-targeted immunotherapeutic vaccine approaches in AML maintenance, potentially supporting sentiment for similar immunotherapy platforms.

Primarily US biotech sentiment; could influence pre-market positioning in small-cap oncology vaccine peers.

Limited direct global read-through, but reinforces the broader appetite for late-stage oncology immunotherapy data.

Counterpoint

OS benefit is based on topline primary endpoint analysis after 80 deaths; investors may wait for full secondary endpoint and subgroup details before fully de-risking regulatory outcomes.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Subject of the 8-K; reports positive pivotal Phase 3 REGAL OS results for GPS and outlines FDA engagement and BLA preparation plans.

  • Galinpepimut-S (GPS)

    WT1-targeted immunotherapeutic cancer vaccine evaluated as AML maintenance monotherapy in REGAL.

  • REGAL trial

    Phase 3 randomized registrational trial evaluating GPS in AML patients in second or later remission who cannot undergo allogeneic stem cell transplantation.

  • U.S. Food and Drug Administration (FDA)

    Company plans to meet to discuss accelerated filing strategy and regulatory path forward.

Related articles

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.

$SLSHighAI 9/10

Why is Sellas Life Sciences stock surging today?

Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.